CY1125005T1 - Συμπλοκα υαλουρονανης με φαρμακευτικως δραστικες ουσιες, μεθοδοι και συνθεσεις - Google Patents

Συμπλοκα υαλουρονανης με φαρμακευτικως δραστικες ουσιες, μεθοδοι και συνθεσεις

Info

Publication number
CY1125005T1
CY1125005T1 CY20221100151T CY221100151T CY1125005T1 CY 1125005 T1 CY1125005 T1 CY 1125005T1 CY 20221100151 T CY20221100151 T CY 20221100151T CY 221100151 T CY221100151 T CY 221100151T CY 1125005 T1 CY1125005 T1 CY 1125005T1
Authority
CY
Cyprus
Prior art keywords
hyaluronan
pharmaceutically active
ester
compositions
methods
Prior art date
Application number
CY20221100151T
Other languages
English (en)
Inventor
Bengt Lindqvist
Rune Ringom
Original Assignee
Synartro Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synartro Ab filed Critical Synartro Ab
Publication of CY1125005T1 publication Critical patent/CY1125005T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Μια μέθοδος για τη κατασκευή ενός συμπλόκου υαλουρονάνης που περιλαμβάνει υαλουρονάνη σε μορφή διαλύματος ή γέλης, που αντιδρά με την υαλουρονάνη σε μορφή διαλύματος ή γέλη με αντιδραστήρια ανυδρίτη για να παράσχει έναν ημί- εστέρα υαλουρονάνη με μια αλυσίδα μήκους L μεταξύ της υαλουρονάνης και της ομάδας εστέρα, και ακολούθως πρόσδεση του ημί- εστέρα υαλουρονάνης με μια φαρμακευτικώς δραστική ένωση. Ένα σύμπλοκο υαλουρονάνης περιλαμβάνει υαλουρονάνη που έχει ελεύθερες ομάδες ημί- εστέρων και μια φαρμακευτικώς δραστική ένωση προσδεμένη με την υαλουρονάνη μέσω ομάδων ημί- εστέρων, όπου οι ομάδες ημί- εστέρων έχουν αλυσίδες μήκους 2-9 ατόμων. Το σύμπλοκο υαλουρονάνης είναι κατάλληλο για χρήση σε διάφορες μεθόδους θεραπείας στην ιατρική ή την κτηνιατρική και για τη παρασκευή ενός φαρμακευτικού σκευάσματος για χρήση στην ιατρική ή στη κτηνιατρική.
CY20221100151T 2014-02-27 2022-02-22 Συμπλοκα υαλουρονανης με φαρμακευτικως δραστικες ουσιες, μεθοδοι και συνθεσεις CY1125005T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461945491P 2014-02-27 2014-02-27
PCT/IB2015/051331 WO2015128787A1 (en) 2014-02-27 2015-02-21 Hyaluronan conjugates with pharmaceutically active substances, methods and compositions

Publications (1)

Publication Number Publication Date
CY1125005T1 true CY1125005T1 (el) 2023-01-05

Family

ID=52693002

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20221100151T CY1125005T1 (el) 2014-02-27 2022-02-22 Συμπλοκα υαλουρονανης με φαρμακευτικως δραστικες ουσιες, μεθοδοι και συνθεσεις

Country Status (14)

Country Link
US (3) US10660906B2 (el)
EP (2) EP3988121A1 (el)
CA (1) CA2974611C (el)
CY (1) CY1125005T1 (el)
DK (1) DK3226905T3 (el)
ES (1) ES2905606T3 (el)
HR (1) HRP20220176T1 (el)
HU (1) HUE057871T2 (el)
LT (1) LT3226905T (el)
PL (1) PL3226905T3 (el)
PT (1) PT3226905T (el)
RS (1) RS62909B1 (el)
SI (1) SI3226905T1 (el)
WO (1) WO2015128787A1 (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3226905T (pt) * 2014-02-27 2022-01-19 Synartro Ab Conjugados de hialuronano com substâncias farmaceuticamente ativas, métodos e composições
TWI662971B (zh) * 2017-03-14 2019-06-21 日商生化學工業股份有限公司 關節疾患處置用組成物及含有該組成物的套組
TWI840445B (zh) 2018-11-16 2024-05-01 日商生化學工業股份有限公司 水性組成物及其用途、注射套組、醫藥組成物及其製造方法、生成抑制方法
CN113750255B (zh) * 2021-09-30 2023-10-31 大连民族大学 环境响应型透明质酸-鬼臼毒素前药胶束及其制备方法和应用
WO2024038087A1 (en) 2022-08-16 2024-02-22 Synartro Ab Method for preparing sterile compositions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE442820B (sv) 1984-06-08 1986-02-03 Pharmacia Ab Gel av tverbunden hyaluronsyra for anvendning som glaskroppssubstitut
IT1281877B1 (it) 1995-05-10 1998-03-03 Fidia Advanced Biopolymers Srl Sali di metalli pesanti di succinil derivati dell'acido ialuronico e loro impiego come potenziali agenti terapeutici
IT1281876B1 (it) 1995-05-10 1998-03-03 Fidia Advanced Biopolymers Srl Acido ialuronico e suoi derivati esterei per la preparazione di matrici per il rilascio controllato di farmaci.
IT1294797B1 (it) * 1997-07-28 1999-04-15 Fidia Advanced Biopolymers Srl Uso dei derivati dell'acido ialuronico nella preparazione di biomateriali aventi attivita' emostatica fisica e tamponante
US6644977B1 (en) 1997-12-31 2003-11-11 Schlefring Und Apparatebau Gmbh Assembly for transmitting electrical signals and/or energy
DE60105610T2 (de) * 2000-06-30 2005-01-27 Banyu Pharmaceutical Co., Ltd. Pyrazinonderivate
US20030049253A1 (en) * 2001-08-08 2003-03-13 Li Frank Q. Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines
JP2004099581A (ja) * 2002-09-09 2004-04-02 Masashi Takahashi 抗炎症剤
CA2750725C (en) 2004-01-07 2014-10-21 Seikagaku Corporation Spacer derivative for hyaluronic acid and non-steroidal anti-inflammatory drug residues
JP5043364B2 (ja) * 2006-05-01 2012-10-10 生化学工業株式会社 多糖誘導体の製造方法
IE20070900A1 (en) 2007-12-12 2009-06-24 Eurand Pharmaceuticals Ltd New anticancer conjugates
US20130053405A1 (en) * 2009-10-06 2013-02-28 Ulrich Hersel Carrier linked paliperidone prodrugs
SG11201400815TA (en) * 2011-10-12 2014-09-26 Ascendis Pharma Ophthalmology Division As Prevention and treatment of ocular conditions
GB2510587B (en) * 2013-02-07 2020-05-20 Orthopaedic Res Uk Biospecific agents for bone
PT3226905T (pt) * 2014-02-27 2022-01-19 Synartro Ab Conjugados de hialuronano com substâncias farmaceuticamente ativas, métodos e composições

Also Published As

Publication number Publication date
US20160367684A1 (en) 2016-12-22
EP3226905B1 (en) 2021-12-22
RS62909B1 (sr) 2022-03-31
WO2015128787A1 (en) 2015-09-03
US20220168320A1 (en) 2022-06-02
US20200237783A1 (en) 2020-07-30
ES2905606T3 (es) 2022-04-11
LT3226905T (lt) 2022-03-10
PL3226905T3 (pl) 2022-04-19
US11229656B2 (en) 2022-01-25
EP3988121A1 (en) 2022-04-27
CA2974611A1 (en) 2015-09-03
CA2974611C (en) 2022-07-12
US10660906B2 (en) 2020-05-26
HUE057871T2 (hu) 2022-06-28
HRP20220176T1 (hr) 2022-04-29
DK3226905T3 (da) 2022-01-24
EP3226905A1 (en) 2017-10-11
US11642357B2 (en) 2023-05-09
SI3226905T1 (sl) 2022-04-29
PT3226905T (pt) 2022-01-19

Similar Documents

Publication Publication Date Title
CY1125005T1 (el) Συμπλοκα υαλουρονανης με φαρμακευτικως δραστικες ουσιες, μεθοδοι και συνθεσεις
CY1120969T1 (el) Παραγωγα κινοξαλινης χρησιμα ως τροποποιητες fgfr κινασης
CO2018013978A2 (es) Derivados de ácido borónico y usos terapéuticos de los mismos.
CY1123361T1 (el) Παραγωγο ισοϊνδολινης, ενδιαμεσο, μεθοδος παρασκευης, φαρμακευτικη συνθεση και χρηση αυτου
BR112018007876A2 (pt) derivado de benzofurano, método de preparação do mesmo e uso do mesmo na medicina
CL2020000075A1 (es) Carboxamidas como moduladores de los canales de sodio.
EA201791692A1 (ru) 4H-ПИРРОЛО[3,2-c]ПИРИДИН-4-ОНОВЫЕ ПРОИЗВОДНЫЕ
CY1123627T1 (el) Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου
EA201890125A1 (ru) Новые гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их
BR112018011781A2 (pt) molécula biespecífica possuindo um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de pd-1 e um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de ctla-4, e composição farmacêutica
CY1125033T1 (el) Σκευασμα μεθοτρεξατης
CY1114458T1 (el) Πυρρολοβενζοδιαζεπινες και προϊοντα συζευξης αυτων
CY1125179T1 (el) Παραγωγα πυραζολιου χρησιμα ως αναστολεις της πρωτεïνης ενεργοποιησης της 5-λιποξυγενασης (flap)
PE20170776A1 (es) Nuevos anticuerpos anti-mfi2 y metodos de uso
EA201792034A1 (ru) Замещенные трициклические гетероциклические соединения
PE20220297A1 (es) Neutralizacion del virus chikungunya mediada por anticuerpos
BR112022004972A2 (pt) Anticorpos, ácidos nucleicos isolados, células hospedeiras isoladas, métodos de produção de um anticorpo, de produção de um anticorpo biespecífico e de tratamento de um indivíduo, anticorpos biespecíficos, composição farmacêutica, anticorpo, anticorpo biespecífico ou composição farmacêutica, combinação de um anticorpo, uso do anticorpo, uso de uma combinação do anticorpo e métodos para reduzir a inflamação e para melhorar a descamação e/ou de erupção cutânea e combinação para uso
EA202091400A1 (ru) Производные пиррола в качестве ингибиторов асс
BR112018010279A2 (pt) novos anticorpos anti-emr2 e métodos de uso
CY1122892T1 (el) Παραγωγα 3-(καρβοξυμεθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου
UY35997A (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CY1122882T1 (el) Παραγωγα 3-(καρβοξυαιθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου
ECSP16096831A (es) Derivados de naftiridinadiona
CO6321234A2 (es) Derivados de acido fenilacetico como moduladores de la inflamacion
BR112018012884A2 (pt) novos anticorpos anti-mmp16 e métodos de uso